The Healthy Life Approach Podcast
A new large-scale study of 217,000 women has sparked major conversation about GLP-1 medications (including tirzepatide and other GLP-1 receptor agonists) and their possible relationship to breast cancer risk reduction. In this episode of The Healthy Life Approach Podcast, I break down a recent University of Pennsylvania study presented at ASCO 2026 that found women taking GLP-1 medications were diagnosed with breast cancer at a significantly lower rate than those not taking them. But what does that actually mean? We go beyond the headlines to explain: * What a retrospective cohort study actually tells us (and what it doesn’t) * Why propensity score matching matters for interpreting results * The difference between relative risk vs absolute risk reduction * How GLP-1 medications may influence metabolic health, insulin levels, inflammation, and estrogen pathways * Why this finding is not proof of causation, but an important signal for future research As someone who personally takes a GLP-1 medication, I also share my lived experience with metabolic changes during menopause, type 2 diabetes, and weight gain, and why this research is personally meaningful. Book Kristen to speak -> https://www.healthylifeapproach.com/speaker [https://www.healthylifeapproach.com/speaker] This episode is for education and awareness only, not medical advice. Always consult your healthcare provider for personalized guidance. If you’re interested in GLP-1 drugs, metabolic health, menopause, breast cancer research, or emerging medical studies, this breakdown will help you understand what the data actually says beyond the viral headlines. #GLP1 #BreastCancerAwareness #Tirzepatide #MetabolicHealth #HealthPodcast
31 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af The Healthy Life Approach Podcast-fællesskabet!